NCT01972711View on ClinicalTrials.gov

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-36385625 as a single oral dose of 50 mg

DRUG

Amisulpride

Amisulpride as a single oral dose of 400 mg

DRUG

Placebo

single oral dose placebo

Trial Locations (2)

OX3 7JX

Department of Psychiatry, University of Oxford, Warneford Hospital, Headington

M13 9PT

University of Manchester, Neuroscience and Psychiatry Unit, Manchester

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01972711 - Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics | Biotech Hunter | Biotech Hunter